<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899219</url>
  </required_header>
  <id_info>
    <org_study_id>ID-087-104</org_study_id>
    <nct_id>NCT04899219</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects</brief_title>
  <official_title>An Open-label, Single-dose Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, single-dose study to investigate the pharmacokinetics of ACT-1014-6470 in&#xD;
      subjects with severe renal impairment compared to control subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, open-label, single-dose, parallel-group, Phase 1 study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK of ACT-1014-6470 - Cmax</measure>
    <time_frame>Blood samples for PK analysis will be drawn at various time points (total duration: up to 6 days in Group A, up to 4 days in Group B).</time_frame>
    <description>For both Group A (subjects with severe renal impairment) and Group B (control subjects)</description>
  </primary_outcome>
  <other_outcome>
    <measure>PK of ACT-1014-6470 - Tmax</measure>
    <time_frame>Blood samples for PK analysis will be drawn at various time points (total duration: up to 6 days in Group A, up to 4 days in Group B).</time_frame>
    <description>For both Group A (subjects with severe renal impairment) and Group B (control subjects)</description>
  </other_outcome>
  <other_outcome>
    <measure>Group B (control subjects): PK of ACT-1014-6470 - AUC0-inf</measure>
    <time_frame>Blood samples for PK analysis will be drawn at various time points (total duration: up to 6 days in Group A, up to 4 days in Group B).</time_frame>
    <description>For both Group A (subjects with severe renal impairment) and Group B (control subjects)</description>
  </other_outcome>
  <other_outcome>
    <measure>Group B (control subjects): PK of ACT-1014-6470 - T1/2</measure>
    <time_frame>Blood samples for PK analysis will be drawn at various time points (total duration: up to 6 days in Group A, up to 4 days in Group B).</time_frame>
    <description>For both Group A (subjects with severe renal impairment) and Group B (control subjects)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group A (subjects with severe renal impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (control subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-1014-6470 40 mg</intervention_name>
    <description>ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.</description>
    <arm_group_label>Group A (subjects with severe renal impairment)</arm_group_label>
    <arm_group_label>Group B (control subjects)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent in a language understandable to the subject prior to any&#xD;
             study-mandated procedure.&#xD;
&#xD;
          -  Male or female subject aged at least 18 years at Screening.&#xD;
&#xD;
          -  Women of non-childbearing potential (e.g. post-menopausal)&#xD;
&#xD;
        Additional inclusion criteria for subjects with severe renal impairment (Group A).&#xD;
&#xD;
        - Severe renal function impairment as confirmed at Screening based on an estimated&#xD;
        glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD)&#xD;
        formula of &lt; 30 mL/min (not on dialysis).&#xD;
&#xD;
        Additional inclusion criteria for control subjects (Group B):&#xD;
&#xD;
          -  Normal renal function as confirmed at Screening based on eGFR.&#xD;
&#xD;
          -  Each control subject must be matched to the values of one subject with severe renal&#xD;
             impairment based on age (±10 years difference allowed), BMI (±15% difference allowed),&#xD;
             and sex, determined by results at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
        full participation in the study or compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Disclosure Desk</last_name>
    <phone>+41 58 844 1977</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>APEX GmbH</name>
      <address>
        <city>Munich</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

